JP2025500411A5 - - Google Patents
Info
- Publication number
- JP2025500411A5 JP2025500411A5 JP2024537895A JP2024537895A JP2025500411A5 JP 2025500411 A5 JP2025500411 A5 JP 2025500411A5 JP 2024537895 A JP2024537895 A JP 2024537895A JP 2024537895 A JP2024537895 A JP 2024537895A JP 2025500411 A5 JP2025500411 A5 JP 2025500411A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- dose
- antibody
- pharmaceutical composition
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21216714.2 | 2021-12-22 | ||
| EP21216714 | 2021-12-22 | ||
| PCT/EP2022/087393 WO2023118395A1 (en) | 2021-12-22 | 2022-12-22 | Treatment paradigm for an anti-cd19 antibody therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025500411A JP2025500411A (ja) | 2025-01-09 |
| JP2025500411A5 true JP2025500411A5 (https=) | 2026-01-08 |
Family
ID=79018498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024537895A Pending JP2025500411A (ja) | 2021-12-22 | 2022-12-22 | 抗ｃｄ１９抗体療法のための治療パラダイム |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20230357392A1 (https=) |
| EP (1) | EP4453033A1 (https=) |
| JP (1) | JP2025500411A (https=) |
| KR (1) | KR20240131370A (https=) |
| CN (1) | CN119013293A (https=) |
| AU (1) | AU2022419233A1 (https=) |
| CA (1) | CA3255552A1 (https=) |
| CL (2) | CL2024001870A1 (https=) |
| IL (1) | IL313736A (https=) |
| MX (1) | MX2024007649A (https=) |
| TW (1) | TW202334231A (https=) |
| WO (1) | WO2023118395A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2767063C2 (ru) | 2015-08-21 | 2022-03-16 | МорфоСис АГ | Комбинации и их использование |
| US12358983B2 (en) | 2016-10-28 | 2025-07-15 | Incyte Corporation | Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5156840A (en) | 1982-03-09 | 1992-10-20 | Cytogen Corporation | Amine-containing porphyrin derivatives |
| US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| ES2176484T3 (es) | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
| CA2512729C (en) | 2003-01-09 | 2014-09-16 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
| WO2004065416A2 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| WO2004072266A2 (en) | 2003-02-13 | 2004-08-26 | Kalobios Inc. | Antibody affinity engineering by serial epitope-guided complementarity replacement |
| PL2383297T3 (pl) | 2006-08-14 | 2013-06-28 | Xencor Inc | Zoptymalizowane przeciwciała ukierunkowane na CD19 |
| KR101490468B1 (ko) * | 2010-02-04 | 2015-02-06 | 삼성전자 주식회사 | 데이터 처리 장치 및 방법 |
| HRP20220224T1 (hr) * | 2011-08-16 | 2022-04-29 | Morphosys Ag | Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom |
| KR20140064873A (ko) * | 2011-08-16 | 2014-05-28 | 모르포시스 아게 | 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법 |
| AU2015277516A1 (en) * | 2014-06-16 | 2016-12-22 | Xencor, Inc. | Treatment for chronic lymphocytic leukemia (CLL) |
| RU2767063C2 (ru) * | 2015-08-21 | 2022-03-16 | МорфоСис АГ | Комбинации и их использование |
| TW202525340A (zh) * | 2019-10-31 | 2025-07-01 | 美商英塞特公司 | 用於治療白血病或淋巴瘤之抗cd19療法與來那度胺(lenalidomide)的組合 |
| WO2022117799A2 (en) * | 2020-12-04 | 2022-06-09 | Morphosys Ag | Anti-cd19 combination therapy |
-
2022
- 2022-12-22 CA CA3255552A patent/CA3255552A1/en active Pending
- 2022-12-22 KR KR1020247024443A patent/KR20240131370A/ko active Pending
- 2022-12-22 US US18/087,068 patent/US20230357392A1/en not_active Abandoned
- 2022-12-22 WO PCT/EP2022/087393 patent/WO2023118395A1/en not_active Ceased
- 2022-12-22 AU AU2022419233A patent/AU2022419233A1/en active Pending
- 2022-12-22 EP EP22844057.4A patent/EP4453033A1/en active Pending
- 2022-12-22 MX MX2024007649A patent/MX2024007649A/es unknown
- 2022-12-22 JP JP2024537895A patent/JP2025500411A/ja active Pending
- 2022-12-22 IL IL313736A patent/IL313736A/en unknown
- 2022-12-22 TW TW111149579A patent/TW202334231A/zh unknown
- 2022-12-22 CN CN202280090874.3A patent/CN119013293A/zh active Pending
-
2024
- 2024-06-19 CL CL2024001870A patent/CL2024001870A1/es unknown
-
2025
- 2025-02-26 CL CL2025000520A patent/CL2025000520A1/es unknown
- 2025-08-19 US US19/303,673 patent/US20260062483A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025500411A5 (https=) | ||
| US20240009196A1 (en) | Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof | |
| CN106334187B (zh) | 包含特异性识别cd38的抗体和硼替佐米的抗肿瘤组合 | |
| JP4842435B2 (ja) | キメラ抗ｃｄ２０抗体を用いた、循環腫瘍細胞に関連した血液学的悪性疾患の治療 | |
| JP2021524244A5 (https=) | ||
| US20240366756A1 (en) | Combinations and uses thereof | |
| JP2020503260A5 (https=) | ||
| AU2018211258A1 (en) | Compositions comprising anti-CD38 antibodies and lenalidomide | |
| US12194095B2 (en) | Combinations and uses thereof | |
| JP2018534933A5 (https=) | ||
| JP2023524149A5 (https=) | ||
| IL292978A (en) | Preparations containing antibodies against cd-38 carfilzomib | |
| JP2023551559A5 (https=) | ||
| JP2022531408A5 (https=) | ||
| JP2023508496A5 (https=) | ||
| AU2012296907A1 (en) | Combination therapy with an anti - CD19 antibody and a nitrogen mustard | |
| EP4168449A1 (en) | Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpa-cd47 innate immune checkpoint | |
| JP2024540435A5 (https=) | ||
| JP2025509567A5 (https=) | ||
| JP2022521773A5 (https=) | ||
| RU2013127115A (ru) | Комбинированная терапия при в-клеточных лимфомах | |
| JP2025508832A5 (https=) | ||
| RU2025129547A (ru) | Способы применения мультиспецифических связывающих белков | |
| CN118871129A (zh) | 抗tim-3抗体与去甲基化药物的药物组合 | |
| RU2008127884A (ru) | Способы применения cd40-связывающих веществ |